Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Case For Moon: Gateway For Open Ended Exploration, With Planetary Protection Central - On The SpaceShow
- Sweet Irony: The Environmental Impacts Of GMO Sugar Science Denial
- Why We Get Tired When We Stay Up Too Late
- The Real Cost Of Milk
- When It Comes To Replicating Psychology Studies, Good Luck
- We’re Not In Europe Any More: BfR Statement On EDCs Embraces The Risk-Based Approach
- Even Light Drinkers Should Watch For Fatty Liver Disease
- "Mi Cro, I happened upon your global temperature charts recently, and want to be sure I understand..."
- "You make good points. I thank you for them. I am enjoying reading your work. I agree that asteroid..."
- "Oh, okay, glad you aren't worried about little asteroids. Yes I agree, I haven't come across that..."
- "Hello Dario,no copies are made of the same event - the triggering and the data storage are two..."
- "Yes, as the numbers are averages, there is this possibility - actually it happens all the time..."
- Science instruments of NASA's James Webb Space Telescope successfully installed
- Tiny wasp sniffs out, picks up 'good vibrations' to battle ash borer
- Abundance inequality in freshwater communities has an ecological origin
- Family size and education levels: The right support could reverse long-held theory
- New water-quality data on impact of corn, soybeans on nitrate in Iowa streams